[1] Latt NL, Niazi M, Pyrsopoulos NT. Liver transplant allocation policies and outcomes in United States: A comprehensive review. World J Methodol,2022,12:32-42.
[2] Quante M, Benckert C, Thelen A, et al. Experience Since MELD Implementation: How Does the New System Deliver? Int J Hepatol,2012,2012:264015.
[3] 汪涛, 李蕾, 张金彦, 等. 供肝分配合理性的再思考. 肝脏,2019,24:739,755.
[4] Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology,2003,124:91-96.
[5] Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut,2020,69:564-568.
[6] Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2019 Annual Data Report: Liver. Am J Transplant,2021,21 Suppl 2:208-315.
[7] Allen AM, Heimbach JK, Larson JJ, et al. Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation, 2018,102:1710-1716.
[8] Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology,2021,161:1887-1895.e4.
[9] De Souza V, Hadj-Aissa A, Dolomanova O, et al. Creatinine-versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology,2014,59:1522-1531.
[10] Ge J, Kim WR, Lai JC, et al. "Beyond MELD"-Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation. J Hepatol,2022,76:1318-1329.
[11] Kasiske BL, Pyke J, Snyder JJ. Continuous distribution as an organ allocation framework. Curr Opin Organ Transplant,2020,25:115-121.
[12] Snyder JJ, Salkowski N, Wey A, et al. Organ distribution without geographic boundaries: A possible framework for organ allocation. Am J Transplant,2018,18:2635-2640.
[13] Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2021,74:1611-1644.
[14] Lai JC, Rahimi RS, Verna EC, et al. Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study. Gastroenterology,2019,156:1675-1682.
[15] Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl,2017,23:625-633.
[16] Carey EJ, Lai JC. A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. Hepatology,2019,70:1816-1829.
[17] Atiemo K, Skaro A, Maddur H, et al. Mortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (≤15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data. Am J Transplant,2017,17:2410-2419.
[18] 尹依. 医联体信息平台下EHR信息共享影响因素研究: 昆明理工大学, 2021.
[19] Van Vleck TT, Chan L, Coca SG, et al. Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non-alcoholic fatty liver disease at risk for disease progression. Int J Med Inform,2019,129:334-341.
[20] Kawamoto K, Kukhareva P, Shakib JH, et al. Association of an Electronic Health Record Add-on App for Neonatal Bilirubin Management With Physician Efficiency and Care Quality. JAMA Netw Open,2019,2:e1915343. |
